AUS
NZ
UK
CA
USA
IND
Highlights
- EKF Diagnostics Holdings opened a new fermentation facility in South Bend.
- For FY23, the company secured a profit before tax of £2.1 million as compared to a loss before tax of £8.9 million in FY22.
- The company paid a final dividend of 1.2 pence per share in December 2023, with an ex-dividend date of 02 November 2023.
FTSE AIM All-Share listed EKF Diagnostics Holdings PLC (LSE:EKF) is a UK-based healthcare company engaged in the manufacturing of medical diagnostic products and services. In FY23, EKF opened a new fermentation facility in South Bend.
For the full fiscal year 2023, EKF secured a profit before tax of £2.1 million as compared to a reported loss before tax of £8.9 million in the previous year. Its revenue was recorded at £48.7 million (excluding COVID-related & clinical chemistry sales) in the reporting period. It secured a group cash, net of borrowings, of approximately £4.7 million in FY23.
The company witnessed continued sustainable growth in core business lines. There has been 11%* year-on-year increase in HbA1c testing with Quo-Test® and Quo-Lab® for Diabetes. Its Hematology division saw 10%* YoY rise in Hemoglobin testing with DiaSpect Tm and Hemo Control. Its β-HB LiquiColor® reagent increased by 4%* in the reporting period.
The company paid a final dividend of 1.2 pence per share in December 2023, with an ex-dividend date of 02 November 2023.
Comparing EKF’s growth in 2023 and 2019, the company has witnessed a 2% growth in America alone. Around 48.4% of group activity in 2023 is attributable to the region, Americas.
For Europe, Middle East, and Africa (EMEA), EKF registered 25% growth in 2023 as compared to the year 2019. For 2023, the region EMEA contributed around 41.2%* of group activity.
Top 10 Shareholders:
Around 71.84% of the total shareholdings is held by its top ten shareholders. While Harwood Capital LLP is the biggest shareholder with over 29.15% shareholding, Liontrust Investment Partners LLP is the second biggest shareholder with around 12.09% shareholding in EFK.
Stock Price Performance
EFF’s stock price has dropped by 13.37% in the last one month. It has fallen by 0.72% over the last six months. The stock’s 52-week low and high price stand at GBX 22.20 and GBX 38.22, respectively.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference data for all price data, currency, technical indicators, support, and resistance levels is 20 March 2024. The reference data in this report has been partly sourced from EODHD/Others.
